# NCT03485547 (NCT03485547)

> Study of Venetoclax, a BCL2 Antagonist, for Patients With Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN)

No report yet. It can be ordered.

## Registry

- Registry record: https://clinicaltrials.gov/study/NCT03485547
- Phase: PHASE1
- Status: COMPLETED
- Sponsor: Dana-Farber Cancer Institute
- Conditions: Blastic Plasmacytoid Dendritic Cell Neoplasm
- Interventions: Venetoclax
- Enrollment: 5
- Primary outcome: Dose Limiting Toxicity

## Indexed commentary on NCT03485547 so far

Podcasts, YouTube videos and X posts we have indexed that name the trial. This is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this.

- X threads: 3

## Order

Focused, $750, price fixed at order: https://www.erudio.com/contact?report=nct03485547